AMN Healthcare Reports Q4 and Full Year 2024 Results
AMN Healthcare Reports Q4 and Full Year 2024 Results AMN Healthcare Services, Inc. (NYSE: AMN), a leader in total talent solutions for healthcare organizations across the U.S., has announced its financial results for the fourth quarter (Q4) and full year…
Prisma Health Saves $450M with Systemwide Transformation
Prisma Health Saves $450M with Systemwide Transformation Prisma Health, South Carolina’s largest healthcare provider, has long been at the forefront of delivering exceptional care across the state. However, the challenges faced by the organization during the COVID-19 pandemic – including…
Henry Schein Highlights Innovative Dental Solutions at 2025 Chicago Dental Society Meeting
Henry Schein Highlights Innovative Dental Solutions at 2025 Chicago Dental Society Meeting Henry Schein, Inc. is showcasing its innovative digital equipment, technology solutions, and business services at the 2025 Chicago Dental Society Midwinter Meeting, taking place from February 20 to…
Baxter Reports Q4 and Full-Year 2024 Results
Baxter Reports Q4 and Full-Year 2024 Results Baxter International Inc. (NYSE: BAX), a leader in the global medtech industry, reported its financial results for the fourth quarter and full year ending December 31, 2024. The company also provided financial guidance…
MinuteClinic® and Emory Healthcare Expand Primary Care Access in Georgia
MinuteClinic® and Emory Healthcare Expand Primary Care Access in Georgia MinuteClinic®, the healthcare clinic located inside select CVS Pharmacy® stores, is teaming up with Emory Healthcare Network, the largest clinically integrated healthcare network in Georgia, to enhance primary care access…
Celltrion Presents New LIBERTY Study Analyses at ECCO Congress on SC Infliximab Efficacy and Safety
Celltrion Presents New LIBERTY Study Analyses at ECCO Congress on SC Infliximab Efficacy and Safety Celltrion presented new post hoc analyses of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) at the 20th European Crohn’s and Colitis Organisation (ECCO) Congress, shedding…
Allurion Closes Offering and Private Placement to Advance GLP-1 Pipeline
Allurion Closes Offering and Private Placement to Advance GLP-1 Pipeline Allurion Technologies, Inc. (NYSE: ALUR), a company focused on ending obesity, announced the successful closing of its previously announced registered direct offering. The offering involved institutional investors purchasing 900,000 shares…
NextGen Healthcare Selected by Elite DNA to Improve Patient and Staff Experiences
NextGen Healthcare Selected by Elite DNA to Improve Patient and Staff Experiences NextGen Healthcare, a top provider of innovative healthcare technology, has been selected by Elite DNA Behavioral Health, based in Florida, to deliver a scalable platform that will support…
CareDx Study Shows AlloSeq cfDNA Accurately Detects Organ Rejection
CareDx Study Shows AlloSeq cfDNA Accurately Detects Organ Rejection CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine for transplant patients, announced new findings published in Transplant International. The study demonstrated that the performance of AlloSeq™ cfDNA in detecting allograft…
Phase 2 Trial Begins for Early Alzheimer’s with Sinaptica’s Neuromodulation System
Phase 2 Trial Begins for Early Alzheimer’s with Sinaptica’s Neuromodulation System Sinaptica Therapeutics, Inc., a clinical-stage company focused on developing personalized neuromodulation therapies for Alzheimer’s and other neurodegenerative diseases, has announced the launch of a Phase 2 clinical trial for…
Variational AI Raises $5.5 Million to Launch Foundation Model for Drug Discovery
Variational AI Raises $5.5 Million to Launch Foundation Model for Drug Discovery Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, has successfully closed its oversubscribed $5.5 million Seed extension round. Enki™ is designed…
OS Therapies Granted Patent for OST-HER2 Commercial Manufacturing
OS Therapies Granted Patent for OST-HER2 Commercial Manufacturing OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company focused on immunotherapies and targeted drug conjugates for cancer treatment, announced today that it has received a Notice of Allowance from the United…